EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced a strategic expansion of its cancer testing capability.
EDX Medical is to launch comprehensive hereditary germline cancer testing products and services designed to accurately predict if family members of cancer patients are at increased risk from the disease.
The first test to be made available to health professionals in the UK is a pan-cancer test which achieves 99% sensitivity and identifies mutations in 70 genes known to be associated with cancers which have a strong inherited, genetic component including prostate, breast, colorectal, pancreatic and ovarian cancers in a single test.
EDX Medical’s comprehensive hereditary germline cancer testing products will enable doctors to advise family members of cancer patients on lifestyle choices and actions they can take to delay or prevent onset of the disease. Family members include grandparents, parents, children, siblings and other blood relatives.
The test will be available later this summer through private healthcare providers and via specific NHS Genetic and Genomic Testing Centres in cases where family members of cancer patients can be screened for genetic risk of cancer. In addition, EDX Medical will provide a support service for healthcare professionals with the test
